Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Oncolytic adenoviral vectors and methods and uses related thereto

A viral vector and adenovirus technology, applied in the fields of life science and medicine, can solve the problem of insufficient induction of anti-tumor immunity, and achieve the effect of improving cancer treatment and reducing side effects

Active Publication Date: 2017-03-22
TARGOVAX
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Viral replication alone, although immunogenic, is often insufficient to induce effective antitumor immunity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oncolytic adenoviral vectors and methods and uses related thereto
  • Oncolytic adenoviral vectors and methods and uses related thereto
  • Oncolytic adenoviral vectors and methods and uses related thereto

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0112] Embodiment 1. Cloning three kinds of D24-GM-CSF type viruses

[0113] -PCR out hGM-CSF,

[0114] - Generate SunI / MunI site => 445bp (pORF-GM-CSF as template)

[0115] -SunI / MunI digestion of PCR product and pTHSN

[0116] - sticky end ligation =>

[0117] - PmeI linearized pShuttle-D24+pTG3602 => pAd5-D24

[0118] - Ad5-D24-GM-CSF (SEQ ID NO 8: E1A region with D24 deletion in nucleotide positions 563-1524 and ciliary region in nucleotide positions 30490-32236)

[0119] Homologous recombination: SrfI linearized pAd5-D24+FspI linearized pTHSN-GM-CSF=>pAd5-D24-GM-CSF

[0120] PacI linearization & transfection => Ad5-D24-GM-CSF

[0121] All stages of cloning were confirmed by PCR and multiple restriction digests. The shuttle plasmid pTHSN-GMCSF was sequenced. The absence of wild-type El was confirmed by PCR. The El region, transgene and cilia were checked by sequencing and PCR in the final virus, which was then taken to a clean laboratory for production. To this en...

Embodiment 2

[0124] Example 2. In vitro analysis of D24-GM-CSF virus

[0125] D24-GM-CSF-type virus was studied using the MTS cell-killing assay in lung cancer cells (A549), breast cancer stem cell-derived explants (J IMT-1), and breast cancer cells (MDA-MB-436) in vitro efficacy. The MTS assay is currently the standard method used to assess cell survival in cancer gene therapy publications. Ad5Luc1 is a replication defective virus and served as a negative control. Ad5wt is the wild type Ad5 virus (strain Ad300wt) and was used as a positive control. Ad5-d24-E3 contains an isogenic 24bp deletion in El but is complete in E3. VP denotes viral particle.

[0126] In conclusion, Ad5-D24-GMCSF had similar oncolytic activity to the positive control in vitro, and thus the production of the transgene did not compromise the oncolytic ability of the virus ( Figure 5a -c). Similar data were shown for Ad5 / 3-D24-GM-CSF and Ad5-RGD-D24-GM-CSF ( Figure 5d ).

[0127] To test whether Ad5D24-GMCSF ...

Embodiment 3

[0128] The pretreatment analysis of embodiment 3 transduction

[0129] I. Infection of tumor cells with Ad5Luc1

[0130] To check that tumors can be infected by Ad5-based viruses, biopsies taken from tissues were homogenized and infected with Ad5Luc1 encoding luciferase according to standard infection protocols. Briefly, the cells seeded in the wells were washed twice with PBS, the virus was thawed and resuspended in a minimal amount of growth medium and poured gently over the cells. Infection was carried out for 30 minutes, after which the cells were washed again in PBS and the appropriate amount of complete growth medium was added. Luciferase quantification was assessed after 24 hours. Note that only a small amount of tissue was obtained, so the number of cells could not be calculated, nor could the amount of virus corrected to the amount of tissue be calculated. Therefore, no quantitative analysis was performed, but qualitative data showed successful gene transfer in pat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the fields of life science and medicine. In particular, the invention relates to cancer therapy. More particularly, the present invention relates to oncolytic adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The invention also relates to the use of said vector in the manufacture of a medicament for the treatment of cancer in a subject, and to methods of treating cancer in a subject. Furthermore, the present invention relates to methods of producing GM-CSF in cells and increasing a tumor-specific immune response in a subject, as well as to the use of the oncolytic adenoviral vectors of the present invention for producing GM-CSF in cells and in subjects Use to increase tumor-specific immune response in patients.

Description

[0001] field of invention [0002] The invention relates to the fields of life science and medicine. In particular, the invention relates to cancer therapy. More particularly, the present invention relates to oncolytic adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The invention also relates to the use of said vector in the manufacture of a medicament for the treatment of cancer in a subject, and to methods of treating cancer in a subject. In addition, the present invention relates to methods of producing GM-CSF in cells and increasing tumor-specific immune responses in subjects, and to the use of the oncolytic adenoviral vectors of the present invention for producing GM-CSF in cells and in subjects Use to increase tumor-specific immune response in patients. Background technique [0003] Cancer can be treated with surgery, hormonal therapy, chemotherapy, and / or radiation therapy, but in many cases, cancers that are often characterized ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/861C07K14/535A61K35/761A61P35/00A61P35/02A61K35/76
CPCA61K35/76A61K35/761A61K38/00A61P35/00A61P35/02C07K14/535C12N7/00C12N15/86C12N2710/10332C12N2710/10343C12N2710/10345C12N2810/6018
Inventor A·海明基A·卡内尔瓦V·切鲁洛S·佩索宁
Owner TARGOVAX
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com